×

zbMATH — the first resource for mathematics

Data monitoring in complex clinical trials: Which treatment is ”better”? (English) Zbl 0825.62899
MSC:
62P10 Applications of statistics to biology and medical sciences; meta analysis
PDF BibTeX XML Cite
Full Text: DOI
References:
[1] Alling, D.W., Early decision in the Wilcoxon two-sample test, J as a, 58, 713-720, (1963)
[2] DeMets, D.L., Statistical aspects of early termination in the beta-blocker heart attack trial, Controlled clinical trials, 5, 362-372, (1984)
[3] Follmann, D.; Wittes, J.; Cutler, J., The use of subjective rankings in clinical trials with an application to cardiovascular disease (with discussion), Statist. med., 11, 427-454, (1992)
[4] Haybittle, J.L., Repeated assessment of results in clinical trials of cancer treatment, British J. radiology, 44, 793-797, (1971)
[5] Herson, J., Predictive probability early termination plans for phase II clinical trials, Biometrics, 35, 775-783, (1979) · Zbl 0423.62056
[6] Lakatos, E., Sample sizes based on the log-rank statistic in complex clinical trials, Biometrics, 44, 229-241, (1988) · Zbl 0707.62262
[7] Lan, K.K.G.; DeMets, D.L., Discrete sequential boundaries for clinical trials, Biometrika, 70, 659-663, (1983) · Zbl 0543.62059
[8] Lan, K.K.G.; DeMets, D.L., Changing frequency of interim analysis in sequential monitoring, Biometrics, 45, 1017-1020, (1989)
[9] Lan, K.K.G.; DeMets, D.L., Group sequential procedures: calendar versus information time, Statist. med., 8, 1191-1198, (1989)
[10] Lan, K.K.G.; DeMets, D.L.; Halperin, M., More flexible sequential and nonsequential designs in long-term clinical trials, Comm. statist., A13, 2339-2353, (1984)
[11] Lan, K.K.G.; Friedman, L., Monitoring boundaries for adverse effects in long-term clinical trials, Controlled clinical trials, 7, 1-7, (1986)
[12] Lan, K.K.G.; Simon, R.; Halperin, M., Stochastically curtailed tests in long-term clinical trials, Comm. statist., C1, 207-219, (1982) · Zbl 0501.62078
[13] Lan, K.K.G.; Wittes, J.T., The B-value: a tool for monitoring data, Biometrics, 44, 579-585, (1988)
[14] Mantel, N., Evaluation of survival data and two new rank order statistics arising in its consideration, Cancer chemotherapy reports, 50, 163-170, (1966)
[15] O’Brien, P.C.; Fleming, T.R., A multiple testing procedure for clinical trials, Biometrics, 35, 549-556, (1979)
[16] Pocock, S.J., Group sequential methods in the design and analysis of clinical trials, Biometrika, 64, 191-199, (1977)
[17] Proschan, M.A.; Follmann, D.A.; Waclawiw, M.A., Effects of assumption violations on type I error rate in group sequential monitoring, Biometrics, 48, 1131-1144, (1992)
[18] Spiegelhalter, D.J.; Freedman, L.S.; Blackburn, P.R., Monitoring clinical trials: conditional or predictive power?, Controlled clinical trials, 7, 8-17, (1986)
[19] Young, N., A multicenter trial of antithymocyte globulin in aplastic anemia and related diseases, Blood, 72, 1861-1869, (1988)
[20] Zucker, D.; Wittes, J., Testing the effect of treatment in experiments with correlated binary outcomes, Biometrics, 48, 695-710, (1992)
This reference list is based on information provided by the publisher or from digital mathematics libraries. Its items are heuristically matched to zbMATH identifiers and may contain data conversion errors. It attempts to reflect the references listed in the original paper as accurately as possible without claiming the completeness or perfect precision of the matching.